Every lipid nanoparticle (LNP) is born in a fraction of a second. Lipids dissolved in an organic solvent meet an aqueous buffer carrying the payload, the solvent is diluted away almost instantly, and the lipids, suddenly insoluble, assemble into nanoscale particles. This process, spontaneous assembly driven by solvent exchange, is the manufacturing principle behind virtually every modern LNP platform. Because assembly is triggered and shaped by the changing chemistry of the two mixing phases, the solvent system is not a passive carrier. It is an active design variable that determines how the entire formulation behaves.
The solvent system covers three linked sets of decisions. The organic phase defines how the lipid components, including the ionizable lipid, cholesterol, helper phospholipid, and PEG-lipid, are delivered into the mixing zone. The aqueous phase defines the charge state of the ionizable lipid and the accessibility of the payload. The process conditions, namely phase ratio, mixing intensity, dilution timing, and solvent removal, define how quickly and uniformly those environments change. Each decision cascades directly into critical quality attributes, which is why solvent decisions deserve the same systematic attention as lipid selection during lipid nanoparticle formulation development.
The practical stakes are high. The same lipid composition can produce particles from 40 nm to well over 200 nm, encapsulation efficiencies from below 50% to above 95%, and stable or aggregation-prone products depending on solvent conditions alone. In practical terms, the solvent system influences four families of outcomes:
Assembly behavior: how quickly lipids precipitate, how many nuclei form at the moment of mixing, and how large each nucleus grows before the population is frozen in place.
Payload encapsulation: whether nucleic acids or hydrophobic drugs are captured inside particles as they form, or left behind in solution.
Product quality: particle size, size distribution, morphology, surface charge, and colloidal stability.
Functional performance: cellular uptake, endosomal escape, and ultimately the potency of the delivered payload in in vitro and in vivo settings.
The organic phase carries all four lipid components into the mixing zone as a true molecular solution, and its physical chemistry, including polarity, water miscibility, lipid solubility, and viscosity, sets the starting conditions for self-assembly and therefore the structure of the finished particle.
LNP formation begins the instant the organic stream meets the aqueous stream. A solvent that is fully miscible with water diffuses rapidly into the aqueous phase, and water diffuses simultaneously into the organic stream. Within this transient mixing zone, the polarity of the lipid environment rises sharply, and amphiphilic lipids that were comfortably dissolved in neat solvent abruptly lose solubility, a transition known as desolvation. If this supersaturation event is fast and uniform, many small nuclei form at nearly the same moment and grow into a monodisperse population. If it is slow or uneven, nucleation and growth overlap in time, broadening the size distribution. Three requirements follow:
Complete water miscibility: the solvent must mix with water in all proportions, so the polarity transition happens through diffusion alone rather than across phase boundaries.
Appropriate polarity: polar enough to keep all lipids dissolved at process concentration, yet not so polar that lipids remain soluble after dilution.
Fast exchange kinetics: solvent and water must interdiffuse faster than lipids assemble, so the chemistry of the mixing zone, not the flow geometry, defines the product.
Self-assembly presupposes a true solution, and incomplete dissolution is one of the most underestimated sources of LNP variability. Cholesterol and saturated helper phospholipids such as DSPC have limited solubility in pure ethanol at room temperature, and solubility drops further when the solvent is chilled or contaminated with absorbed water. When any component approaches its solubility limit, the feed composition drifts away from the intended molar ratios, precipitate can deposit inside tubing or the micromixer, and the final particles reflect an unknown composition rather than the designed one. Practical countermeasures include building a solubility map for the specific lipid blend, using binary solvent mixtures such as ethanol with tert-butanol or isopropanol where neat ethanol falls short, warming the feed to 30-40 °C, and confirming feed clarity immediately before mixing. Because cholesterol sits closest to its solubility limit in many blends, focused LNP cholesterol optimization often resolves what initially looks like a mixing failure.
Viscosity controls how fast everything else happens. By the Stokes-Einstein relationship, the diffusion coefficient of a dissolved species is inversely proportional to solvent viscosity, so high-viscosity solvents slow the interdiffusion of solvent, water, and lipid in the mixing zone. Slower exchange stretches the time window over which nucleation occurs, lets early nuclei grow while others are still forming, and broadens the size distribution. Viscous organic streams also resist precise pumping and distort the volumetric ratio actually delivered inside microfluidic devices. The low viscosity of ethanol, approximately 1.1 mPa·s at 20 °C, is one of its quieter advantages over heavier alcohols.
Ethanol is the benchmark organic phase for good reasons: complete water miscibility supports rapid desolvation; many commonly studied LNP lipid blends remain fully dissolved at 10-50 mg/mL total lipid; low viscosity enables fast mixing and accurate pumping; and ethanol is readily cleared by diafiltration or dialysis. Alternatives earn consideration when the lipid blend, payload, or downstream process demands it:
tert-Butanol: fully water-miscible and compatible with freeze-drying routes, since LNPs formed via tert-butanol dilution can be lyophilized with well-preserved size, though its higher viscosity requires adjusted mixing settings.
Methanol and isopropanol: methanol dissolves some lipids better but raises handling toxicity concerns with little process advantage; isopropanol extends solubility limits for difficult blends but slows mixing through roughly twice the viscosity of ethanol.
Solvent blends and solvent-aided systems: ethanol-rich blends combine low viscosity with added solvency, while emerging solvent-aided approaches using less conventional solvents such as pyridine have been reported to reorganize LNP internal structure and improve functional potency in pulmonary delivery models.
Table 1. Physical Properties of Organic Solvents Commonly Considered for LNP Formulation.
| Solvent | Water Miscibility | Viscosity (mPa·s, 20 °C) | Lipid Solubility | Practical Note |
| Ethanol | Complete | ~1.1 | Good for most blends at 10-50 mg/mL | Default benchmark; easy removal |
| tert-Butanol | Complete | ~3.3 (25 °C) | Good; useful for cholesterol-rich blends | Supports freeze-drying routes; melts at 25.5 °C |
| Methanol | Complete | ~0.6 | Stronger than ethanol for some lipids | Handling toxicity limits its use |
| Isopropanol | Complete | ~2.4 | Strong; extends dissolution limits | Higher viscosity slows mixing |
| Ethanol blends | Complete | Between components | Tunable; raises total lipid capacity | Useful when neat ethanol is insufficient |
Table 2. Reported Effects of Organic Solvent Choice on LNP Formation Outcomes.
| Solvent System | Particle Size Trend | Encapsulation Impact | Key Consideration |
| Ethanol (neat) | Baseline; 50-100 nm typical at standard FRR | Reference performance | Balanced kinetics and solubility |
| tert-Butanol | Comparable after mixing adjustment | Comparable; supports solid-state products | Slower diffusion; retune FRR and TFR |
| Methanol-containing | Smaller particles reported for some lipids | Variable | Toxicity outweighs benefits in most programs |
| Isopropanol-containing | Larger size or broader PDI unless mixing intensified | Improves loading of solubility-limited lipids | Compensate viscosity with mixing energy |
| Solvent-aided (e.g., pyridine) | Maintained with adjusted conditions | Reported internal restructuring and potency gains | Requires dedicated development |
BOC Sciences provides systematic organic phase screening, lipid solubility mapping, and alternative solvent evaluation to de-risk your solvent decisions before they cost you batches.
The aqueous phase is often treated as a fixed recipe, typically an acidic citrate buffer, yet its variables control the electrostatic events that capture the payload. Buffer pH determines the charge state of the ionizable lipid, buffer species contributes ions that can screen electrostatic interactions, and additives modulate both assembly and long-term stability.
The ionizable lipid is the hinge on which the whole system turns. Ionizable lipids used in modern ionizable lipid nanoparticles are engineered with apparent pKa values near 6.0-6.5, meaning they are almost fully protonated and positively charged at the acidic pH of formulation, around pH 4.0, and essentially neutral at physiological pH. At formulation pH, the positively charged headgroups electrostatically bind the phosphate backbone of RNA or DNA, concentrating the payload at the very moment the particles form. The practical windows are narrow:
Too acidic (below pH 3): protonation is complete, but acid-catalyzed RNA hydrolysis accelerates.
Optimal window (pH 3.5-4.5): near-complete protonation with acceptable payload stability; this window anchors most published LNP processes.
Approaching the lipid pKa: protonation becomes incomplete, complexation weakens, and encapsulation efficiency falls even though mixing conditions are unchanged.
Because the target pH depends on the specific lipid rather than a universal rule, ionizable lipid selection and formulation pH are best optimized as a matched pair.
Citrate buffer between 10 and 50 mM at pH 4.0 is the de facto standard, and for good reason: it buffers effectively in the formulation range, contributes a known ionic strength, and behaves predictably during downstream neutralization. Alternatives carry trade-offs. Acetate buffers closer to pH 4.8 but delivers lower capacity per millimole; histidine, with a pKa near 6.0, suits mildly acidic conditions. Beyond pH maintenance, the buffer species influences assembly through its ions: citrate is a multivalent anion and screens electrostatic interactions more strongly per millimole than monovalent acetate, which can translate into measurably different particle sizes and internal organization at equal nominal pH. Screening buffer species alongside pH, rather than fixing citrate by default, is a low-cost way to gain formulation headroom, and dedicated LNP buffer screening studies cover species, concentration, and pH as one coordinated design space.
Ionic strength is a double-edged variable. At low ionic strength, electrostatic repulsion between newly formed particles remains strong, keeping particles small and mutually separated during the vulnerable growth phase. As ionic strength rises, dissolved ions shield the charges on lipid headgroups and on the nucleic acid payload: repulsion between particles weakens, allowing fusion and growth, while the attraction between lipid and payload that drives encapsulation weakens in parallel. The net effect is well documented, as adding 150 mM sodium chloride to the formulation buffer generally increases particle size, while low-salt acidic buffers favor the small, uniform particles most programs target. The buffer itself contributes ions, so citrate concentration and any added salt must be optimized together with the phase ratio rather than in isolation.
Additives extend the aqueous phase beyond the buffer itself, and the common families serve distinct purposes:
Sugars (sucrose, trehalose): provide cryoprotection and lyoprotection for frozen or freeze-dried products and adjust tonicity without adding ionic strength.
Chelators (EDTA): sequester trace divalent metals that catalyze RNA degradation during processing and storage.
Amino acids and polyols: act as mild stabilizers that moderate interfacial stress during mixing and buffer exchange in sensitive formulations.
Additive identity interacts with the solvent system: sugars raise aqueous viscosity slightly and shift the mixing regime, and a sugar that protects particles during freeze-thaw can alter particle size at the moment of formation if included from the start. Systematic LNP excipient screening and cryoprotectant screening separate these coupled effects and identify additive packages that stabilize the product without compromising assembly.
Table 3. Aqueous Phase Parameters and Their Effects on LNP Formation and Quality.
| Parameter | Typical Range | Effect on Assembly | Effect on Product Quality |
| Buffer pH | pH 3.5-4.5 (lipid-dependent) | Controls ionizable lipid protonation and complexation | Direct driver of encapsulation efficiency |
| Buffer species | Citrate, acetate, histidine, succinate | Multivalent species screen charge more strongly | Influences size, internal organization |
| Buffer concentration | 10-50 mM | Sets baseline ionic strength | Higher concentration trends toward larger particles |
| Added salt | 0-150 mM NaCl | Shields electrostatic repulsion | Size increases; encapsulation can decline |
| Sugars and additives | 2-10% w/v sucrose or trehalose | Minor viscosity increase; interfacial stabilization | Cryo/lyoprotection; storage stability |
Even with both phases fully optimized, the way they meet rewires the outcome. Phase ratio, mixing intensity, ethanol fraction at the point of precipitation, and the timing of post-mixing dilution collectively define the solvent history of the batch, and solvent history is what the particles remember.
The flow rate ratio (FRR), the volumetric ratio of aqueous to organic streams, is the most direct size lever available to the formulator. A typical starting point of 3:1 produces particles in the 60-90 nm range for many standard compositions. Raising the FRR to 5:1 or 10:1 accelerates solvent dilution at the point of contact, increases momentary supersaturation, and generates a denser population of nuclei that share the available lipid, yielding smaller particles, often down to 40-60 nm. Lowering the FRR toward 1:1 keeps the mixing zone ethanol-rich for longer, favors growth over nucleation, and shifts the population toward 100-200 nm with broader distributions. Because FRR changes the local solvent environment rather than the chemistry of the phases, it can tune size across a wide range without touching the formulation itself, which is why it anchors most microfluidic LNP production processes.
Lipids do not precipitate from ethanol-water mixtures at a single universal composition; each lipid system has a critical solvent window below which the lipids lose solubility and assemble. For many commonly used LNP lipid systems this window falls roughly between 50% and 75% ethanol. The local ethanol fraction inside the mixing zone therefore decides when nucleation starts and how long growth continues: rapid passage through the critical window produces a burst of simultaneous nucleation and uniform particles, while slow passage allows early nuclei to grow as later ones are still forming. After the streams combine, the bulk ethanol fraction, near 25% at a 3:1 FRR, remains high enough that particles continue to reorganize, which is why post-mixing handling matters as much as mixing itself.
The total flow rate (TFR) through the mixer sets how much mixing energy is delivered and how fast solvent and water interdiffuse. When mixing is fast, on the order of a few milliseconds, solvent exchange outpaces lipid assembly and the assembly environment becomes effectively uniform across the whole stream. Under this regime, particle size is governed by FRR and composition, and the process is insensitive to small changes in TFR, a hallmark of a robust, scalable process. When mixing is slow, nucleation occurs in a heterogeneous solvent landscape and size becomes sensitive to flow rate and device geometry, complicating scale-up. Mixer architecture matters here: staggered herringbone micromixers induce chaotic advection to fold the streams together, while hydrodynamic flow focusing confines the organic stream in a thin sheath to shorten diffusion distances. Verifying that a formulation sits in the mixing-insensitive regime, and moving it there if it does not, is a central objective of structured LNP process optimization.
Particles that emerge from the mixer are not finished. Residual ethanol, typically 20-40% depending on FRR, keeps lipid membranes mobile and permits continued growth, fusion, and internal reorganization. Immediate dilution of the collected stream with cold acidic buffer, commonly 10- to 20-fold, quenches these processes by dropping the ethanol fraction below the level at which lipids remain mobile, stabilizing the particle population as formed. Diluting at formulation pH keeps the ionizable lipid protonated and the particles compact, while diluting directly into neutral buffer triggers premature neutralization that can destabilize freshly formed particles.
Final solvent removal then prepares the product for use: dialysis suits small-scale research batches, while tangential flow filtration (TFF) scales efficiently. The sequence of buffer exchange matters as much as the technology. In a two-step approach, ethanol is first removed under acidic conditions while the particles remain protonated and compact, and only then is the buffer exchanged to a neutral storage formulation. Reported benefits include reduced particle fusion and a lower fraction of empty particles compared with single-step neutralization. A detailed discussion of LNP solvent removal strategies is available in our related resource, and dedicated free payload removal services ensure unencapsulated nucleic acid is cleared to the level the analytical method requires.
Table 4. Mixing and Dilution Parameters and Their Effects on LNP Formation.
| Parameter | Typical Setting | Mechanistic Effect | Downstream Impact |
| Flow rate ratio (FRR) | 3:1 standard; 5:1-10:1 for smaller particles | Controls dilution speed and supersaturation | Primary determinant of particle size |
| Total flow rate (TFR) | Mixer-dependent; ms-scale mixing | Sets mixing energy and interdiffusion rate | Process robustness; size sensitivity at low TFR |
| Post-mixing dilution | 10-20x cold acidic buffer | Quenches maturation below membrane mobility threshold | Locks size distribution; prevents fusion |
| Solvent removal method | Dialysis or TFF | Clears ethanol and exchanges buffer | Stability, residual level, empty fraction |
| Neutralization sequence | Two-step: acidic removal, then buffer exchange | Keeps particles protonated during the vulnerable stage | Reduced fusion versus single-step |
BOC Sciences optimizes solvent ratio, mixing intensity, dilution timing, and solvent removal as one coordinated design space, so your particle size survives scale-up.
The process variables described above converge on a set of measurable product attributes. Understanding these cause-and-effect chains turns solvent optimization from trial and error into rational engineering.
Particle size responds to solvent variables in a predictable order of leverage: the flow rate ratio is usually the strongest handle, followed by the ethanol fraction in the mixing zone and the speed of post-mixing dilution. Organic phase choice modifies the baseline, as higher-viscosity solvents shift the achievable size upward unless mixing energy is increased. Size distribution, reported as the polydispersity index (PDI), is governed less by average conditions than by their uniformity: any heterogeneity in mixing, from slow TFR to uneven dilution, appears directly as PDI. Routine nanoparticle size analysis by dynamic light scattering provides the feedback loop that keeps these variables on target from batch to batch.
Encapsulation efficiency (EE) measures the fraction of payload that ends up inside particles rather than free in solution, and solvent system decisions dominate it. Buffer pH alignment with the lipid pKa sets the strength of the electrostatic complexation that captures nucleic acid at the moment of assembly. The speed of ethanol removal then determines whether the payload stays captured: slow removal keeps membranes mobile and lets encapsulated nucleic acid leak or exchange with the medium, while rapid, staged removal locks it in place. The fraction of empty particles follows the same logic, and staged neutralization has been shown to reduce it. One caution deserves emphasis: residual ethanol and incomplete removal of free payload both distort fluorescent assays, so apparent EE problems should first be verified with a validated method. Programs pushing EE upward benefit from structured LNP encapsulation efficiency optimization, and our companion resource on measuring LNP encapsulation efficiency covers assay pitfalls in detail.
Cryo-transmission electron microscopy reveals that LNPs are not structurally interchangeable: some populations show electron-dense cores, where aqueous payload is trapped inside an inverted lipid phase, while others show multilamellar or shell-like organization. The solvent history of the batch strongly influences which structure emerges. Fast precipitation and rapid quenching can freeze nonequilibrium organizations, while slower maturation in residual solvent allows lipids to rearrange toward more ordered states. Because internal organization correlates with how readily the payload escapes the endosome after uptake, two batches with identical size and EE can differ in potency purely on morphology. Direct morphology characterization and structural characterization by cryo-EM and small-angle scattering make this hidden variable visible and actionable.
Stability failures often trace back to solvent handling after the mixer. Residual ethanol at levels above a few percent keeps lipid membranes mobile during storage, so particles slowly fuse and measured size creeps upward over days and weeks. Abrupt changes during buffer exchange, whether a jump in pH, ionic strength, or both, can trigger immediate aggregation in a population that looked pristine at collection. Sugars in the final buffer mitigate both failure modes by stabilizing membranes and moderating osmotic stress. A stability program that tracks size, PDI, and payload retention across storage conditions, supported by dedicated lipid nanoparticle stability studies, converts solvent removal decisions from guesswork into specification.
The solvent system never touches the target cell, yet it shapes every property that determines how the particle behaves once it arrives. Surface presentation of PEG-lipids, which governs protein corona formation and cell association, depends on the assembly and maturation history of the particle; internal lipid organization, which governs endosomal escape, depends on the same history. The result is a familiar frustration: batches with acceptable size, PDI, and EE but weak transfection or silencing activity. When this happens, solvent history is among the first places to look, because it changed the particle without changing the standard analytical fingerprint. Structured LNP transfection troubleshooting connects formulation history to functional outcome and identifies which solvent variable is responsible.
Table 5. Mapping Solvent System Variables to LNP Critical Quality Attributes.
| Solvent Variable | Primary Attribute Affected | Direction of Effect | Monitoring Method |
| Flow rate ratio (FRR) | Particle size | Higher FRR produces smaller particles | DLS, NTA |
| Ethanol fraction at mixing | PDI; nucleation uniformity | Rapid passage through critical window narrows distribution | DLS, cryo-EM |
| Buffer pH vs. lipid pKa | Encapsulation efficiency | Closer alignment raises EE | Fluorescence-based nucleic acid assays,UV assays |
| Ionic strength | Size; aggregation tendency | Higher ionic strength increases size and fusion risk | DLS, zeta potential |
| Removal rate and sequence | Empty fraction; morphology | Staged removal reduces fusion and empty particles | cryo-EM, SEC, stability trending |
| Residual solvent level | Storage stability | Lower residual slows size growth on storage | GC, size trending |
Most solvent-related failures announce themselves through recognizable signatures. The five patterns below account for a large share of troubleshooting requests, and each has a defined diagnostic path.
Cause: The lipid blend exceeds solvent capacity, most often due to cholesterol or saturated helper phospholipids near their solubility limits. Cold solvent, water uptake from humid air, and lipid stocks stored at low temperature all reduce effective solubility.
Indicator: Visible haziness in the organic phase, white deposits in tubing or the micromixer, lipid recovery below the charged amount, and unexplained drift of particle size or composition between batches.
Proposed solution: Build a solubility map for the exact lipid blend across candidate solvents and temperatures. Where neat ethanol is insufficient, move to ethanol-tert-butanol or ethanol-isopropanol blends, reduce total lipid concentration, warm the feed to 30-40 °C, and confirm clarity immediately before mixing.
Cause: Flow rate ratio set too low, mixing energy insufficient for the solvent viscosity, ethanol fraction drifting outside the critical window, or a mixer geometry that leaves the process in the slow-mixing regime where size is flow-sensitive.
Indicator: Z-average above target, PDI above 0.2, high batch-to-batch variability, and the diagnostic signature of size changing measurably when total flow rate changes.
Proposed solution: Screen FRR in steps from 3:1 upward and verify that the process sits in the mixing-insensitive regime. If size remains flow-sensitive, increase mixing energy or switch to a higher-efficiency mixer architecture, and confirm improvements with orthogonal methods rather than DLS alone.
Cause: Buffer pH misaligned with the lipid pKa, suboptimal N/P ratio, ethanol removed so slowly that nucleic acid leaks during maturation, or mixing heterogeneity that leaves regions of the stream under-complexed.
Indicator: Encapsulation efficiency below about 70%, high free nucleic acid in the product, and low payload recovery across the removal step.
Proposed solution: Re-center the formulation pH inside the protonation window for the specific lipid, titrate the N/P ratio, and accelerate ethanol removal with staged acidic diafiltration. Dedicated troubleshooting for LNP encapsulation dissects these variables systematically, and our resource comparing loading capacity and encapsulation efficiency helps distinguish a true formulation limit from an assay artifact.
Cause: Residual ethanol left in the product, abrupt pH or ionic strength jumps during buffer exchange, or a final buffer that provides no membrane-stabilizing components.
Indicator: Particle size rising over hours to weeks in storage, visible aggregation, and drifting zeta potential.
Proposed solution: Define solvent removal endpoints with quantitative residual measurement, adopt staged neutralization, and screen final buffers containing sucrose or trehalose. Because instability frequently appears only at production scale, the practices described in our review of batch reproducibility in scalable LNP production provide a useful audit checklist.
Cause: Solvent history altered internal lipid organization or surface PEG presentation in ways that standard QC does not detect, shifting endosomal escape or cellular association behavior without changing size, PDI, or EE.
Indicator: All release-relevant attributes within specification while transfection or gene silencing in cell culture remains several-fold below expectation.
Proposed solution: Add morphology and structural assays to the characterization panel, compare surface properties across batches with different solvent histories, and run a focused evaluation through nanoparticle in vitro evaluation to connect the process variable to the functional gap.
BOC Sciences provides root-cause troubleshooting across dissolution, mixing, encapsulation, and stability, with analytical confirmation at every step.
Solvent system optimization succeeds when the organic phase, aqueous phase, mixing conditions, and removal process are developed as one connected design space rather than as isolated settings. BOC Sciences supports this work end to end, from early solvent screening through scalable lipid nanoparticle manufacturing, with characterization integrated at every decision point.
Our LNP solvent screening services map the solubility of your exact lipid blend across ethanol, tert-butanol, isopropanol, and their mixtures, at process-relevant concentrations and temperatures. The output is a defined working window for lipid feed concentration and solvent composition, with feed stability verified over realistic hold times, so dissolution failures are engineered out before mixing begins.
We screen buffer pH, species, concentration, ionic strength, and additive packages against your lipid system and payload. Because these variables interact with the organic phase ratio, screening runs as a coordinated matrix that identifies the combination delivering target size, encapsulation, and stability, rather than optimizing each variable against an assumed fixed background.
Using microfluidic platforms spanning staggered herringbone, flow focusing, and scalable mixing geometries, we map FRR, TFR, and dilution timing to particle attributes, verify the mixing-insensitive regime, and lock a process window that transfers reliably to production scale.
We develop staged solvent removal and buffer exchange sequences, including two-step acidic-then-neutral diafiltration, and quantify their effect on empty particle fraction, payload retention, and storage stability. Residual solvent levels are measured directly, and final buffer compositions, including cryoprotectant packages for frozen or lyophilized products, are selected against stability data rather than convention.
Table 6. BOC Sciences Services for LNP Solvent System Optimization.
| Service | Scope | Key Deliverables | Inquiry |
| Organic Phase Solvent Screening and Lipid Solubility Mapping | Solubility mapping across ethanol, tert-butanol, isopropanol, and blends; feed stability verification; concentration window definition | Solvent selection report with defined lipid feed window | Inquiry |
| Aqueous Phase and Buffer System Optimization | Coordinated screening of pH, buffer species, ionic strength, and additives | Ranked aqueous phase conditions with size, EE, and stability data | Inquiry |
| Solvent Ratio and Mixing Process Development | FRR, TFR, and dilution timing mapping; mixing-regime verification; robust process window definition | Operating space with demonstrated flow insensitivity | Inquiry |
| Post-Mixing Solvent Removal and Buffer Exchange Development | Staged diafiltration sequence development; residual solvent quantification; final buffer selection | Removal and exchange protocol; residual data; stability package | Inquiry |
| LNP CQA Characterization and QC Testing | Size, PDI, zeta potential, EE, morphology, and residual solvent testing across development batches | Full CQA panel per batch; trend analysis | Inquiry |
| LNP Process Scale-Up | Transfer of optimized solvent system conditions to production-scale equipment | Scaled process with matched CQA profile | Inquiry |
The solvent system is the hidden architecture of every LNP process. The organic phase determines whether lipids arrive at the mixing zone as a true solution and how abruptly they precipitate; the aqueous phase determines whether the payload is electrostatically captured at the moment of assembly; and the phase ratio, mixing, dilution, and removal conditions determine whether the particles formed in the mixer are the particles that reach the vial. Because these variables jointly control size, distribution, encapsulation, morphology, stability, and ultimately functional potency, solvent system optimization offers one of the highest returns on development effort in the entire LNP workflow. BOC Sciences supports this work with integrated solvent screening, buffer optimization, mixing development, staged solvent removal, and full CQA characterization, helping development teams convert solvent decisions from a source of batch variability into a source of competitive formulation performance.
References
